Table 4.
Anticoagulants and thrombocyte aggregation inhibitors post TAVI (matched cohort).
| Overall | DirectFlow | Edwards Sapien 3 | P-value | |
|---|---|---|---|---|
| ASS (%) | 56.8 | 60.0 | 53.7 | 0.567 |
| Clopidogrel (%) | 88.9 | 95.0 | 82.9 | 0.086 |
| Ticagrelor (%) | 1.2 | 0 | 2.4 | 0.323 |
| Prasugrel (%) | 0 | 0 | 0 | N/A |
| DOAK (%) | 6.2 | 0 | 12.2 | 0.024* |
| Apixaban (%) | 1.2 | 0 | 2.4 | |
| Rivaroxaban (%) | 3.7 | 0 | 7.3 | |
| Dabigatran (%) | 0 | 0 | 0 | |
| Edoxaban (%) | 1.2 | 0 | 2.4 | |
| Vitamin K antagonist | 37.0 | 37.5 | 36.6 | 0.933 |
| Low molecular heparin | 30.9 | 35.0 | 26.8 | 0.429 |
| Fondaparinux | 1.2 | 0 | 2.4 | 0.323 |
Standard thrombocyte aggregation inhibitor regimen was ASS plus Clopidogrel for 3–6 months post-TAVI unless there was an indication for anticoagulation (in patients with atrial fibrillation, thrombosis, or pulmonary embolism), another thrombocyte aggregation inhibitor regimen required according to guidelines (prior myocardial infarction, previous coronary intervention in Clopidogrel non-responders), or an allergic reaction to one of the substances. Patients with indication for anticoagulation received vitamin K antagonist plus Clopidogrel for 3–6 months as first line therapy. DOAK, direct oral anticoagulant.
*
p-values.